Join to view full profile
165 Cambridge StCPZ-7Boston, MA 02114
Dr. Dahl is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Douglas Dahl, MD, is a urologist based in Boston, MA, specializing in minimally invasive surgery and surgical oncology. He completed medical school at Yale School of Medicine in 1992 and pursued residencies in surgery and urology at Mass General Brigham/Brigham and Women's Hospital and Harvard Medical School. Dr. Dahl has expertise in treating prostate cancer, gynecologic oncology, urologic oncology, minimally invasive urologic surgery, and bladder cancer. He has several publications focusing on prostate cancer and minimally invasive urologic surgery. He is involved in clinical trials, including one on paclitaxel and radiation therapy for bladder cancer. Dr. Dahl has received multiple CMS Meaningful Use certifications related to electronic health records from 2013 to 2017.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Harvard Medical SchoolResidency, Urology, 1994 - 1998- Mass General Brigham/Brigham and Women's HospitalResidency, Surgery, 1992 - 1994
Yale School of MedicineClass of 1992
Certifications & Licensure
MA State Medical License 1993 - 2028
ME State Medical License 2020 - 2028
RI State Medical License 2021 - 2028
NH State Medical License 2021 - 2027
American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2013-2017
- CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013-2017
Clinical Trials
- Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer Start of enrollment: 2005 Jul 26
Publications & Presentations
PubMed
- Comprehensive Spatial Transcriptomic Profiling of Cribriform, Intraductal, Atypical Intraductal Proliferation, and Ductal Adenocarcinoma of the Prostate.Ting Zhao, Cole Nawrocki, Linjie Xiong, Linda T Nieman, Todd E Abbott
Laboratory Investigation; a Journal of Technical Methods and Pathology. 2026-09-01 - Spatial Transcriptomics of Micropapillary, Plasmacytoid, and Sarcomatoid Urothelial Carcinoma Reveals Distinct Molecular Landscapes.Ting Zhao, Cole Nawrocki, Linjie Xiong, Linda T Nieman, Philip J Saylor
Laboratory Investigation; a Journal of Technical Methods and Pathology. 2026-08-25 - Pathologic Upgrading in Biopsy Grade Group 1, PI-RADS ≥ 3 Prostate Cancer: Factors Associated With Clinically Significant Disease on Radical Prostatectomy.Alfred A Barney, Shulin Wu, Adam S Feldman, Chin-Lee Wu, Douglas M Dahl
Clinical Genitourinary Cancer. 2026-06-01
Press Mentions
Trimodal Therapy Promising for Recurrent High-Grade T1 Bladder CancerSeptember 12th, 2024- Higher PSA Screening Rates Tied to Lower Metastatic Prostate Cancer IncidenceOctober 28th, 2022
Ultrasound Therapy for Prostate Ca Yields High PSA ResponseMay 7th, 2019
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: